169 related articles for article (PubMed ID: 35377528)
1. PHOSPHATE exporter XPR1/SLC53A1 is required for the tumorigenicity of epithelial ovarian cancer.
Akasu-Nagayoshi Y; Hayashi T; Kawabata A; Shimizu N; Yamada A; Yokota N; Nakato R; Shirahige K; Okamoto A; Akiyama T
Cancer Sci; 2022 Jun; 113(6):2034-2043. PubMed ID: 35377528
[TBL] [Abstract][Full Text] [Related]
2. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
3. The splicing factor DHX38/PRP16 is required for ovarian clear cell carcinoma tumorigenesis, as revealed by a CRISPR-Cas9 screen.
Cona B; Hayashi T; Yamada A; Shimizu N; Yokota N; Nakato R; Shirahige K; Akiyama T
FEBS Open Bio; 2022 Mar; 12(3):582-593. PubMed ID: 34965029
[TBL] [Abstract][Full Text] [Related]
4. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
5. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
[TBL] [Abstract][Full Text] [Related]
6. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
7. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract][Full Text] [Related]
8. Characterization of XPR1/SLC53A1 variants located outside of the SPX domain in patients with primary familial brain calcification.
López-Sánchez U; Nicolas G; Richard AC; Maltête D; Charif M; Ayrignac X; Goizet C; Touhami J; Labesse G; Battini JL; Sitbon M
Sci Rep; 2019 May; 9(1):6776. PubMed ID: 31043717
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
Sekine M; Koh I; Nakamoto K; Nosaka S; Tomono K; Sugimoto J; Kudo Y
Anticancer Res; 2023 Jun; 43(6):2509-2517. PubMed ID: 37247931
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
Xia Y; Ye S; Yang Y; Liu Y; Tong G
Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
[No Abstract] [Full Text] [Related]
11. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells.
Kawabata A; Hayashi T; Akasu-Nagayoshi Y; Yamada A; Shimizu N; Yokota N; Nakato R; Shirahige K; Okamoto A; Akiyama T
Curr Issues Mol Biol; 2022 Apr; 44(4):1587-1596. PubMed ID: 35723366
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma.
Hemachandra LP; Shin DH; Dier U; Iuliano JN; Engelberth SA; Uusitalo LM; Murphy SK; Hempel N
Cancer Res; 2015 Nov; 75(22):4973-84. PubMed ID: 26359457
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
15. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma.
Zaitsu S; Yano M; Adachi S; Miwa M; Katoh T; Kawano Y; Yasuda M
J Ovarian Res; 2023 May; 16(1):93. PubMed ID: 37179337
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
18. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
20. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
